tolododekin alfa

Phase 1Small molecule

tolododekin alfa is one of 63 small molecule programs targeting Cutaneous Squamous Cell Carcinoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cutaneous Squamous Cell CarcinomaActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Cutaneous Squamous Cell Carcinoma (CSCC)Withdrawn

Cutaneous Squamous Cell CarcinomaPhase 1

Active, not recruiting

Non-Small Cell Lung CancerPhase 1

Active, not recruiting

Cutaneous Squamous Cell Carcinoma (CSCC)Phase 1

Withdrawn

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

31 2

Gemzar

GGynecologic Oncology Group

Preclinical

72 3

Lenvima

Eisai

Preclinical

6 4

Imjudo

AstraZeneca

Preclinical

5 5

Vizimpro

Pfizer

Preclinical

4 6

Gilotrif

Boehringer Ingelheim

Preclinical

12 7

Ofev

Boehringer Ingelheim

Preclinical

7 8

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 9

Remeron

OOrganon and Co

Preclinical

1 10

PD-1 Inhibitor

Johnson & Johnson

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Advanced Solid Tumors

NCT06171750

Q4 2028

Phase 1Recruiting

Non-Small Cell Lung Cancer

NCT07027514

Clinical

Trials by Indication[1]

Advanced Solid Tumors1 trial

Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors

Recruiting·AAnkyra Therapeutics, Inc·Phase 1·NCT06171750·97 enrolled

Non-Small Cell Lung Cancer1 trial

A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer

Recruiting·AAnkyra Therapeutics, Inc·Phase 1·NCT07027514·60 enrolled

Cutaneous Squamous Cell Carcinoma (CSCC)1 trial

An Open-Label Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With Resectable, High-Risk Cutaneous Squamous Cell Carcinoma

Withdrawn·AAnkyra Therapeutics, Inc·Phase 1·NCT07100925

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for tolododekin alfa. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — tolododekin alfa compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for tolododekin alfa. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ankyra Therapeutics, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AAnkyra Therapeutics, Inc

tolododekin alfa

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2028

Trials by Indication[1]

Advanced Solid Tumors1 trial

Non-Small Cell Lung Cancer1 trial

Cutaneous Squamous Cell Carcinoma (CSCC)1 trial

References

Drug Info

Quick Facts

Related News